Table 1:
Clinicopathologic characteristics of patients with Rhabdomyoscarcoma with and without anaplasia (Children’s Oncology Group studies, 1997–2013)
| Characteristic | Anaplasia | p-value1 | ||
|---|---|---|---|---|
| None (n=1339) | Focal (n=133) | Diffuse (n=176) | ||
| Age, years | 0.084 | |||
| <1 | 67 (86%) | 4 (5%) | 7 (9%) | |
| 1–9 | 821 (80%) | 92 (9%) | 118 (11%) | |
| ≥10 | 451 (84%) | 37 (7%) | 51 (9%) | |
| Race | 0.15 | |||
| White | 979 (81%) | 103 (8%) | 130 (11%) | |
| Non-white | 235 (85%) | 18 (6%) | 25 (9%) | |
| Unknown | 125 (79%) | 2 (8%) | 21 (13%) | |
| Sex | 0.097 | |||
| Male | 807 (80%) | 86 (9%) | 116 (11%) | |
| Female | 532 (83%) | 47 (7%) | 60 (9%) | |
| Clinical Group | <0.0001 | |||
| I | 210 (71%) | 38 (13%) | 46 (16%) | |
| II | 229 (75%) | 22 (7%) | 56 (18%) | |
| III | 801 (86%) | 63 (7%) | 63 (7%) | |
| IV | 98 (84%) | 10 (8%) | 9 (8%) | |
| Unknown | 1 | - | - | |
| Stage | <0.0001 | |||
| 1 | 550 (76%) | 63 (9%) | 108 (15%) | |
| 2 | 247 (86%) | 17 (6%) | 22 (8%) | |
| 3 | 443 (85%) | 43 (8%) | 37 (7%) | |
| 4 | 98 (84%) | 10 (8%) | 9 (8%) | |
| Unknown | 1 | - | - | |
| Primary Site | <0.00012 | |||
| All favorable sites | 550 (76%) | 65 (9%) | 109 (15%) | |
| Orbit | 169 (82%) | 12 (6%) | 25 (12%) | |
| Head and neck/non-PM | 127 (84%) | 8 (5%) | 16 (11%) | |
| GU, nonbladder/prostate | 254 (69%) | 45 (12%) | 68 (19%) | |
| All unfavorable sites | 789 (86%) | 68 (7%) | 67 (7%) | |
| Parameningeal | 332 (89%) | 21 (6%) | 22 (6%) | |
| Bladder/prostate | 126 (88%) | 10 (7%) | 8 (6%) | |
| Extremity | 128 (81%) | 15 (9%) | 16 (10%) | |
| Other | 203 (83%) | 22 (9%) | 21 (8%) | |
| Tumor invasiveness | 0.0002 | |||
| T1 | 790 (78%) | 87 (9%) | 131 (13%) | |
| T2 | 546 (86%) | 46 (7%) | 45 (7%) | |
| Unknown | 3 | - | - | |
| Lymph node involvement | 0.059 | |||
| N0 | 1091 (80%) | 119 (9%) | 147 (11%) | |
| N1 | 237 (85%) | 14 (5%) | 27 (10%) | |
| Unknown | 11 | - | 2 | |
| Tumor size, cm | ||||
| ≤5 | 763 (82%) | 68 (7%) | 104 (11%) | 0.64 |
| >5 | 547 (81%) | 61 (9%) | 70 (10%) | |
| Unknown | 29 | 4 | 2 | |
| Risk Group | ||||
| High Risk | 98 (83%) | 10 (9%) | 9 (8%) | <0.0001 |
| Intermediate Risk | 573 (87%) | 50 (7%) | 37 (6%) | |
| Low Risk | 667 (77%) | 73 (8%) | 130 (15%) | |
| Unknown | 1 | - | ||
| Study | ||||
| D9602 | 278 (78%) | 41 (11%) | 38 (11%) | <0.0001 |
| D9802 | 71 (89%) | 5 (6%) | 4 (5%) | |
| D9803 | 366 (79%) | 52 (11%) | 44 (10%) | |
| ARST0331 | 252 (75%) | 18 (5%) | 65 (19%) | |
| ARST0531 | 372 (90%) | 17 (4%) | 25 (6%) | |
1
Chi-square test assessing association with anaplasia status (present or absent), after excluding “Unknown” if applicable.
2
Chi-square test assessing favorable vs unfavorable site with anaplasia status